Pérez-Belmonte, L.M.; Ricci, M.; Sanz-Cánovas, J.; Millán-Gómez, M.; Osuna-Sánchez, J.; Ruiz-Moreno, M.I.; Bernal-López, M.R.; López-Carmona, M.D.; Jiménez-Navarro, M.; Gómez-Doblas, J.J.;
et al. Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure. J. Clin. Med. 2021, 10, 3540.
https://doi.org/10.3390/jcm10163540
AMA Style
Pérez-Belmonte LM, Ricci M, Sanz-Cánovas J, Millán-Gómez M, Osuna-Sánchez J, Ruiz-Moreno MI, Bernal-López MR, López-Carmona MD, Jiménez-Navarro M, Gómez-Doblas JJ,
et al. Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure. Journal of Clinical Medicine. 2021; 10(16):3540.
https://doi.org/10.3390/jcm10163540
Chicago/Turabian Style
Pérez-Belmonte, Luis M., Michele Ricci, Jaime Sanz-Cánovas, Mercedes Millán-Gómez, Julio Osuna-Sánchez, M. Isabel Ruiz-Moreno, M. Rosa Bernal-López, MarÃa D. López-Carmona, Manuel Jiménez-Navarro, Juan J. Gómez-Doblas,
and et al. 2021. "Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure" Journal of Clinical Medicine 10, no. 16: 3540.
https://doi.org/10.3390/jcm10163540
APA Style
Pérez-Belmonte, L. M., Ricci, M., Sanz-Cánovas, J., Millán-Gómez, M., Osuna-Sánchez, J., Ruiz-Moreno, M. I., Bernal-López, M. R., López-Carmona, M. D., Jiménez-Navarro, M., Gómez-Doblas, J. J., Lara, J. P., & Gómez-Huelgas, R.
(2021). Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure. Journal of Clinical Medicine, 10(16), 3540.
https://doi.org/10.3390/jcm10163540